Evotec, CHDI Foundation extend strategic drug discovery collaboration in Huntington’s disease

Evotec SE and CHDI Foundation have announced the extension of their 20-year collaboration focused on developing treatments for Huntington's disease. This partnership, initiated in 2006, is one of Evotec’s largest strategic alliances and utilizes Evotec’s comprehensive neuroscience platform. The collaboration covers a wide range of services, including target validation, stem-cell research, high-content screening, and biomarker discovery, all aimed at advancing the scientific understanding and treatment of Huntington's disease.

Both organizations emphasize the significance and success of their long-standing relationship. Dr. Craig Johnstone, COO of Evotec, expressed pride in the continued contribution to combating Huntington’s disease, highlighting the cooperative efforts with CHDI. Dr. Robert Pacifici, CSO of CHDI, noted the critical role Evotec has played in CHDI’s preclinical research programs, underscoring the value of their scientific partnership in the mission to develop effective therapeutics for Huntington's disease patients.

CHDI Foundation is a nonprofit biomedical research organization solely dedicated to Huntington's disease, managing a diverse portfolio of research projects through a collaborative virtual model. This approach connects innovative research, drug discovery, and clinical development to overcome delays in therapeutic advancement. Evotec, a global life sciences company, partners with numerous pharmaceutical and biotechnology companies to create pioneering therapeutic solutions across various underserved medical fields, aiming to develop a leading portfolio of innovative treatments

Click here to read the original news story.